Close Menu

hepatitis

Johns Hopkins researchers have developed a proof-of-concept test for research use that they hope to eventually refine for clinical use at the point of care.

The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said. 

The test adds to the firm's current portfolio of 30 infectious disease and oncology tests that use its Sentosa PCR and NGS workflow.

One of the applications seeks premarket approval to run the Vitros immunodiagnostic HIV combo assay on the Vitros 3600 system.

The test could be useful to up to 2.2 million patients with chronic HBV to determine whether treatment is working and whether it can be stopped. 

The firm launched the service in part because it recognized that consumers increasingly prefer to pay for their healthcare services out of pocket and without having to get physician referrals. 

Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.

The test enables donor screening laboratories to use PCR-based diagnostic technology to screen donated blood and plasma.

Professional, molecular, and tissue diagnostics sales continued to grow during the first three quarters, while diabetes care sales remained in decline.

Pages